Product NDC: | 63323-304 |
Proprietary Name: | Piperacillin and Tazobactam |
Non Proprietary Name: | PIPERACILLIN SODIUM,TAZOBACTAM SODIUM |
Active Ingredient(s): | 36; 4.5 g/1; g/1 & nbsp; PIPERACILLIN SODIUM,TAZOBACTAM SODIUM |
Administration Route(s): | INTRAVENOUS |
Dosage Form(s): | INJECTION, POWDER, FOR SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 63323-304 |
Labeler Name: | APP Pharmaceuticals, LLC |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA090498 |
Marketing Category: | ANDA |
Start Marketing Date: | 20110531 |
Package NDC: | 63323-304-74 |
Package Description: | 1 INJECTION, POWDER, FOR SOLUTION in 1 BOX (63323-304-74) |
NDC Code | 63323-304-74 |
Proprietary Name | Piperacillin and Tazobactam |
Package Description | 1 INJECTION, POWDER, FOR SOLUTION in 1 BOX (63323-304-74) |
Product NDC | 63323-304 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | PIPERACILLIN SODIUM,TAZOBACTAM SODIUM |
Dosage Form Name | INJECTION, POWDER, FOR SOLUTION |
Route Name | INTRAVENOUS |
Start Marketing Date | 20110531 |
Marketing Category Name | ANDA |
Labeler Name | APP Pharmaceuticals, LLC |
Substance Name | PIPERACILLIN SODIUM; TAZOBACTAM SODIUM |
Strength Number | 36; 4.5 |
Strength Unit | g/1; g/1 |
Pharmaceutical Classes | beta Lactamase Inhibitor [EPC],beta Lactamase Inhibitors [MoA] |